| Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed. | |
| | |
MedLine Citation:
|
PMID: 16172549 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Relapse after an initial response to infliximab therapy poses a problem for maintenance treatment. AIM: To assess the effects of increasing the infliximab dosage in Crohn's disease (CD) patients who initially responded but flared during maintenance therapy. METHODS: This was an observational study. Twelve CD patients with both inflammatory and fistulizing manifestations were included. All patients initially responded to 5 mg/kg of infliximab, relapsed during maintenance therapy, and were treated with 10 mg/kg. The Harvey-Bradshaw index, the fistula activity, and steroid use were assessed before and after treatment with the increased dose of infliximab. RESULTS: The mean Harvey-Bradshaw index score after flare-up during treatment with 5 mg/kg of infliximab was 13.5+/-3.7. Treatment with 10 mg/kg, in a mean of 3.3 infusions, decreased the activity score to a mean of 8.8+/-2.5. Two patients were weaned off prednisone, and a reduced dose was possible in the other steroid-treated patients. CONCLUSIONS: Increasing the infliximab dose may be beneficial in CD patients who initially responded to therapy, but relapsed during maintenance with the lower dosage. |
| | |
Authors:
|
Yoram Menachem; Benjamin Avidan; Alexandra Lavy; Alon Lang; Eytan Bardan; Herma Fidder; Simon Bar-Meir; Yehuda Chowers |
Related Documents
:
|
20195879 - The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in taiw... 23471549 - Letrozole usage adjuvant to gonadotropins for ovulation induction for patients with clo... 20061299 - Rationale for leptin-replacement therapy for severe lipodystrophy. 20924159 - Cost-effectiveness of biological therapy in remission induction of moderate to severe p... 20532579 - Laryngeal involvement in behcet's disease-a challenge for treatment. 9145299 - Pathological evaluation of effect of anti-rheumatic drugs on type ii collagen-induced a... 3935869 - Lhrh-agonist treatment in clinical and experimental human breast cancer. 508549 - Gentamicin pharmacokinetics in kwashiorkor. 21251179 - Ly2189265, a long-acting glucagon like-peptide-1 analog, demonstrated dose-dependent in... |
Publication Detail:
|
Type: Journal Article Date: 2005-09-16 |
Journal Detail:
|
Title: Digestion Volume: 72 ISSN: 0012-2823 ISO Abbreviation: Digestion Publication Date: 2005 |
Date Detail:
|
Created Date: 2005-10-25 Completed Date: 2006-01-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0150472 Medline TA: Digestion Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 124-8 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2005 S. Karger AG, Basel. |
Affiliation:
|
Department of Gastroenterology, Chaim Sheba Medical Center, Tel-Hashomer, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / administration & dosage* Crohn Disease / drug therapy*, pathology Female Gastrointestinal Agents / administration & dosage* Humans Male Middle Aged Recurrence Statistics, Nonparametric Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/infliximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Serum antibodies in first-degree relatives of patients with IBD: a marker of disease susceptibility?...
Next Document: Edkins and a century of acid suppression.